tbuckley/cabot-search huggingface dataset:
Ethics of genetic testing and research in sport: a position statement from the Australian Institute of Sport
Authors: Nicole Vlahovich, Peter A Fricker, Matthew A Brown, David Hughes
Journal: British Journal of Sports Medicine (2016)

As Australia's peak high-performance sport agency, the Australian Institute of Sport (AIS) has developed this position statement to address the implications of recent advances in the field of genetics and the ramifications for the health and well-being of athletes. Genetic testing has proven of value in the practice of clinical medicine. There are, however, currently no scientific grounds for the use of genetic testing for athletic performance improvement, sport selection or talent identification. Athletes and coaches should be discouraged from using direct-to-consumer genetic testing because of its lack of validation and replicability and the lack of involvement of a medical practitioner in the process. The transfer of genetic material or genetic modification of cells for performance enhancement is gene doping and should not be used on athletes. There are, however, valid roles for genetic research and the AIS supports genetic research which aims to enhance understanding of athlete susceptibility to injury or illness. Genetic research is only to be conducted after careful consideration of a range of ethical concerns which include the provision of adequate informed consent. The AIS is committed to providing leadership in delivering an ethical framework that protects the well-being of athletes and the integrity of sport, in the rapidly changing world of genomic science.
In Vivo Functional Dissection of the Chromosome 13q14 Tumor Suppressor Locus Reveals That Extent of Deletions Impacts Disease Course and Phenotype
Authors: Marie Lia, Amanda Carette, Hongyan Tang, Qiong Shen, Tongwei Mo, Govind Bhagat, Riccardo Dalla-Favera, Ulf Klein
Journal: Blood (2011)
Analysis of Ribosomal Protein Genes Associated with Diamond Blackfan Anemia (DBA) In German DBA Patients and Their Relatives
Authors: Jessica Moetter, Mutlu Kartal, Joerg Meerpohl, Alexandra Fischer, Thorsten Simon, Sandra Urbaniak, Shinsuke Hirabayashi, Friedrich Kapp, Peter Noellke, Christian Kratz, Charlotte M Niemeyer, Marcin W. Wlodarski
Journal: Blood (2011)
Long-Term Experience with Allogeneic Bone Marrow Transplant (BMT) in Chronic Myeloid Leukemia
Authors: Alicia Inés Enrico, Ana Basquiera, Juan Jose Napal, Ana Gabriela Sturich, Maria Virginia Prates, Juan Garcia, Sebastian Yantorno, Santiago Milone, Alicia Navickas, Jorge Milone
Journal: Blood (2011)
Intravenous (IV) Iron Supplementation in Patients with Chemotherapy-Induced Anemia (CIA) Receiving Darbepoetin alfa Every 3 Weeks (Q3W): Iron Parameters in a Randomized Controlled Trial.
Authors: Christian Lerchenmueller, Faress Husseini, Bernd Gaede, Tony Mossman, Tamas Suto, An Vanderbroek
Journal: Blood (2006)
CSL362: A Monoclonal Antibody to Human Interleukin-3 Receptor (CD123), Optimized for NK Cell-Mediated Cytotoxicity of AML Stem Cells
Authors: Samantha J. Busfield, Mark Biondo, Mae Wong, Hayley S. Ramshaw, Erwin M Lee, Kirstee Martin, Souravi Ghosh, Hal Braley, Vesna Tomasetig, Con Panousis, Gino Vairo, Andrew W. Roberts, Simon Z. He, Naomi Sprigg, Daniel Thomas, Mark DeWitte, Richard B. Lock, Angel F. Lopez, Andrew Nash
Journal: Blood (2012)
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi
Authors: Carlo Visco, Annalisa Chiappella, Luca Nassi, Caterina Patti, Simone Ferrero, Daniela Barbero, Andrea Evangelista, Michele Spina, Annalia Molinari, Luigi Rigacci, Monica Tani, Alice Di Rocco, Graziella Pinotti, Alberto Fabbri, Renato Zambello, Silvia Finotto, Manuel Gotti, Angelo M Carella, Flavia Salvi, Stefano A Pileri, Marco Ladetto, Giovannino Ciccone, Gianluca Gaidano, Marco Ruggeri, Maurizio Martelli, Umberto Vitolo
Journal: The Lancet Haematology (2016)
Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-Risk MDS and MDS/AML (PODAC).
Authors: Seunghoon Han, Jae-Ho Yoon, Seung-Ah Yahng, Seung-Hwan Shin, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Seok Lee, Chang-Ki Min, Hee-je Kim, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park, Dong-Seok Yim, Yoo-Jin Kim
Journal: Blood (2012)
Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.
Authors: Ingo G.H. Schmidt-Wolf, Thomas Moehler, Hartmut Goldschmidt, Thomas Geer, Rolf Kleinschmidt, Tobias Gaska, Uwe Janssens, Joerg Schubert, Patrick Brueck, Michael R. Clemens, Wolfgang Bair, Gernot Seipelt, Michael Schleuning, Corinna Hahn-Ast, Susanne Herz, Marie von Lilienfeld-Toal, Ralph Naumann, Marcus Gorschlueter, Axel Glasmacher
Journal: Blood (2006)
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category
Authors: E Muchtar, A Dispenzieri, S K Kumar, R P Ketterling, D Dingli, M Q Lacy, F K Buadi, S R Hayman, P Kapoor, N Leung, R Chakraborty, W Gonsalves, R Warsame, T V Kourelis, S Russell, J A Lust, Y Lin, R S Go, S Zeldenrust, R A Kyle, S V Rajkumar, M A Gertz
Journal: Leukemia (2016)
Clinical-Biomarker Correlations in Adult AML Patients in a Phase I Trial of AVN944 Support Observations of Clinical Effect and Provide Hypotheses for Patient Selection Criteria for Further Clinical Trials.
Authors: Rebecca B. Klisovic, Steven Coutre, Tibor J. Kovacsovics, Hagop M. Kantarjiam, Guido J. Tricot, Jeffrey W. Strovel, Thomas Genna, David K. Bol, Michael Hamilton, Beverly S. Mitchell
Journal: Blood (2007)
In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.
Authors: Devendra K. Hiwase, Deborah L. White, Verity A. Saunders, Phuong Dang, Amity Venables, Laura Eadie, Steph Zrim, L. Bik To, Junia V. Melo, Timothy P. Hughes
Journal: Blood (2007)
Systematic analysis of chromatin interactions at disease associated loci links novel candidate genes to inflammatory bowel disease
Authors: Claartje A. Meddens, Magdalena Harakalova, Noortje A. M. van den Dungen, Hassan Foroughi Asl, Hemme J. Hijma, Edwin P. J. G. Cuppen, Johan L. M. Björkegren, Folkert W. Asselbergs, Edward E. S. Nieuwenhuis, Michal Mokry
Journal: Genome biology (2016)

Genome-wide association studies (GWAS) have revealed many susceptibility loci for complex genetic diseases. For most loci, the causal genes have not been identified. Currently, the identification of candidate genes is predominantly based on genes that localize close to or within identified loci. We have recently shown that 92 of the 163 inflammatory bowel disease (IBD)-loci co-localize with non-coding DNA regulatory elements (DREs). Mutations in DREs can contribute to IBD pathogenesis through dysregulation of gene expression. Consequently, genes that are regulated by these 92 DREs are to be considered as candidate genes. This study uses circular chromosome conformation capture-sequencing (4C-seq) to systematically analyze chromatin-interactions at IBD susceptibility loci that localize to regulatory DNA.Using 4C-seq, we identify genomic regions that physically interact with the 92 DRE that were found at IBD susceptibility loci. Since the activity of regulatory elements is cell-type specific, 4C-seq was performed in monocytes, lymphocytes, and intestinal epithelial cells. Altogether, we identified 902 novel IBD candidate genes. These include genes specific for IBD-subtypes and many noteworthy genes including ATG9A and IL10RA. We show that expression of many novel candidate genes is genotype-dependent and that these genes are upregulated during intestinal inflammation in IBD. Furthermore, we identify HNF4α as a potential key upstream regulator of IBD candidate genes.We reveal many novel and relevant IBD candidate genes, pathways, and regulators. Our approach complements classical candidate gene identification, links novel genes to IBD and can be applied to any existing GWAS data.
Overall Survival Advantage and Acceptable Safety Profile with Fludarabine In Combination with Alemtuzumab (FluCam) In Previously Treated Patients with Advanced Stage Chronic Lymphocytic Leukemia
Authors: Andreas Engert, Liana Gercheva, Galina Pilipenko, Tadeusz Robak, Jingyang Wu, Cynthia A. Sirard, Thomas Elter
Journal: Blood (2010)
Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities
Authors: Michele Cavo, Sara Bringhen, Carolina Terragna, Paola Omedè, Giulia Marzocchi, Marina Ruggeri, Sandra Durante, Maria Teresa Petrucci, Tommasina Guglielmelli, Giulia Benevolo, Vittorio Montefusco, Franco Narni, Antonietta Falcone, Catello Califano, Anna Baraldi, Silvana Pasini, Piero Galieni, Fortunato Morabito, Mariella Grasso, Daniela Gottardi, Vincenzo Rizzo, Mario Boccadoro, Nicoletta Testoni, Antonio Palumbo
Journal: Blood (2010)
Insight Into HCDR3 Restrictions in CLL by Analysis of Incomplete IGHD-IGHJ Rearrangements: Further Evidence that Somatic Selection Shapes the Expressed CLL Immunoglobulin Repertoire.
Authors: Eugenia Tsakou, Andreas Agathagelidis, Myriam Boudjoghra, Thorsten Raff, Antonis Dagklis, Georgios Bourikas, Helene Merle-Beral, Achilles Anagnostopoulos, Nikolaos Laoutaris, Monika Bruggemann, Frederic Davi, Kostas Stamatopoulos, Chrysoula Belessi
Journal: Blood (2009)
ACTR-15. A PHASE I STUDY OF THE ONCOLYTIC VIRUS DNX-2401 AND A SHORT COURSE TEMOZOLOMIDE FOR GLIOBLASTOMA AT FIRST RECURRENCE
Authors: Sonia Tejada, Ricardo Diez Valle, Jaime Gallego, Marta M Alonso, Joana Peterkin
Journal: Neuro-Oncology (2016)

DNX-2401 is an oncolytic adenovirus that has been tested in clinical studies for treating recurrent glioblastoma. It has also been shown in animal models of cancer that DNX-2401 exhibits synergy when combined with a variety of agents, including temozolomide. A clinical study of DNX-2401 followed by temozolomide was conducted to investigate this further. To investigate safety, OR, and OS following treatment with DNX-2401 and temozolomide. Patients at first recurrence after prior surgery, radiotherapy, and temozolomide were treated (n=31). A tumor resection or biopsy was performed to confirm recurrent disease. All patients received a single intraparenchymal injection of 3e10 vp DNX-2401 followed by 4 cycles of 150 mg/m2temozolomide (7 days on/7 days off) 2–4 weeks later. Ninety-four percent (94%) of patients completed all 4 planned cycles. Grade 3–4 adverse events were consistent with toxicities associated with temozolomide (lymphopenia) or the underlying disease (headache, mental impairment). Several objective responses were observed. One patient with unmethylated MGMT is alive 30 months after study treatment in the absence of progression or need for further treatment. Two additional patients are alive after 23 months. The study is ongoing and results will be updated. The study results demonstrate that DNX-2401 with temozolomide can be safely administered. Indications of clinical activity after recurrence supports additional investigation in this setting and evaluation in front-line glioblastoma.
Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants.
Authors: Alena Y. Zhang, Blaine W. Robinson, Kajia Kao, Kathryn Behling, Meenakshi Devidas, Todd Alonzo, Susana C. Raimondi, Andrew Carroll, Robert J. Arceci, Alan Gamis, Stephen P. Hunger, Gregory H. Reaman, Richard C. Harvey, Cheryl L. Willman, Li-San Wang, Carolyn A. Felix
Journal: Blood (2008)
Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models
Authors: Deepak Sampath, Elizabeth Punnoose, Erwin R. Boghaert, Lisa Belmont, Jun Chen, Franklin Peale, Nguyen Tan, Walter Darbonne, Peng Yue, Jason Oeh, Leslie Lee, Wayne J. Fairbrother, Andrew J. Souers, Steve W. Elmore, Joel D. Leverson
Journal: Blood (2012)
Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs.
Authors: Mauricette Michallet, Mohamad Sobh, Jean El-Cheikh, Stéphane Morisset, Anne Sirvent, Oumedaly Reman, Jérôme Cornillon, Reza Tabrizi, Noel Milpied, Jean-Luc Harousseau, Hélène Labussière-Wallet, Franck E. Nicolini, Charles Dumontet, Mohamad Mohty, Michel Attal, Didier Blaise, Philippe Moreau, Hervé Avet-Loiseau
Journal: Blood (2012)
HbQ-Iran [α75 (EF4) Asp→His]/−α3.7/β° IVSII.1 G→A in an Iranian Child: First Reported Case.
Authors: Adriana Muniz, Ronald L. Nagel, Zhoreh Rahimi, Asad V. Raygani, Reza Akramipour, Fariborz Bahremand
Journal: Blood (2006)
Pegylated Liposomal Doxorubicin (PLD), Dexamethasone and Low Dose Thalidomide (DDt): An Active Regimen in the Frontline Therapy for Multiple Myeloma (MM).
Authors: Delva Deauna-Limayo, Suman Kambhampathi, David Bodensteiner, Siddharta Ganguly, Barry Skikne, Karen Wolfe, Holly Smith, Ron Krebill, Dean Merkel, Da Zhang, Carol Blecke, Sarah Spencer, Matthew Mayo
Journal: Blood (2007)
Prognostic Value of Serum Lactate Dehydrogenase (LDH) in Patients with Primary Systemic Amyloidosis Undergoing Stem Cell Transplantation.
Authors: Shaji Kumar, Martha Q. Lacy, Angela Dispenzieri, Suzanne Hayman, Francis K. Buadi, David Dingli, Mark R. Litzow, Morie A. Gertz
Journal: Blood (2007)
Topical Diphencyprone Immunotherapy for Painful Nodular Acral Recurrence of Kaposi Sarcoma
Authors: Calogero Pagliarello, Ignazio Stanganelli, Giuseppe Fabrizi, Claudio Feliciani, Sergio Di Nuzzo
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Angiotensin-Converting Enzyme Inhibition as an Adjunct to Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease
Authors: Katrina J. Curtis, Victoria M. Meyrick, Bhavin Mehta, Gulam S. Haji, Kawah Li, Hugh Montgomery, William D.-C. Man, Michael I. Polkey, Nicholas S. Hopkinson
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Section:ChooseTop of pageAbstract <<MethodsResultsDiscussionConclusionsReferencesCITING ARTICLES
Long Term Follow up of the AML97-Study for Patients with AML Older Than 60 Years: A Study of the East German Hematology and Oncology Study Group (OSHO)
Authors: Christoph Kahl, Rainer Krahl, Haifa Kathrin Al-Ali, Herbert G. Sayer, Antje Schulze, Michael Herold, Mathias Hänel, Sebastian Scholl, Andreas Hochhaus, Lutz Uharek, Georg Maschmeyer, Detlev Hähling, Christian Junghanss, Norma Peter, Dietrich Kämpfe, Erika Kettner, Thomas Heinicke, Thomas Fischer, Ute Kreibich, Hans-Heinrich Wolf, Dietger Niederwieser
Journal: Blood (2014)
Left Ventricular Noncompaction
Authors: Jonathan R. Weir-McCall, Phey Ming Yeap, Carla Papagiorcopulo, Kerrie Fitzgerald, Stephen J. Gandy, Matthew Lambert, Jill J.F. Belch, Ian Cavin, Roberta Littleford, Jennifer A. Macfarlane, Shona Z. Matthew, R. Stephen Nicholas, Allan D. Struthers, Frank Sullivan, Shelley A. Waugh, Richard D. White, J. Graeme Houston
Journal: Journal of the American College of Cardiology (2016)

There is considerable overlap between left ventricular noncompaction (LVNC) and other cardiomyopathies. LVNC has been reported in up to 40% of the general population, raising questions about whether it is a distinct pathological entity, a remodeling epiphenomenon, or merely an anatomical phenotype. The authors determined the prevalence and predictors of LVNC in a healthy population using 4 cardiac magnetic resonance imaging diagnostic criteria. Volunteers >40 years of age (N = 1,651) with no history of cardiovascular disease (CVD), a 10-year risk of CVD < 20%, and a B-type natriuretic peptide level greater than their gender-specific median underwent magnetic resonance imaging scan as part of the TASCFORCE (Tayside Screening for Cardiac Events) study. LVNC ratios were measured on the horizontal and vertical long axis cine sequences. All individuals with a noncompaction ratio of ≥2 underwent short axis systolic and diastolic LVNC ratio measurements, and quantification of noncompacted and compacted myocardial mass ratios. Those who met all 4 criteria were considered to have LVNC. Of 1,480 participants analyzed, 219 (14.8%) met ≥1 diagnostic criterion for LVNC, 117 (7.9%) met 2 criteria, 63 (4.3%) met 3 criteria, and 19 (1.3%) met all 4 diagnostic criteria. There was no difference in demographic or allometric measures between those with and without LVNC. Long axis noncompaction ratios were the least specific, with current diagnostic criteria positive in 219 (14.8%), whereas the noncompacted to compacted myocardial mass ratio was the most specific, only being met in 61 (4.4%). A significant proportion of an asymptomatic population free from CVD satisfy all currently used cardiac magnetic resonance imaging diagnostic criteria for LVNC, suggesting that those criteria have poor specificity for LVNC, or that LVNC is an anatomical phenotype rather than a distinct cardiomyopathy.
Yttrium-90-Ibritumomab Tiuxetan (Zevalin) in Combination with a Fludarabine-Based Reduced Conditioning Regimen (RIC) Followed by Allogenic Stem Cell Transplantation for Advanced/Aggressive Non-Hodgkin's Lymphoma (NHL): A Prospective, Multicentre, Open Phase II Study
Authors: Krimo Bouabdallah, Sabine Furst, Reda Bouabdallah, Stephane Vigouroux, Reza Tabrizi, Cyril Melot, Steven Le Gouill, Nathalie Fegueux, Olivier Tournilhac, Mohamad Mohty, Didier Blaise, noel-Jean Milpied
Journal: Blood (2011)
The Number of Very Small Embryonic Like Stem Cells (VSELs) Decreases During Aging In An IGF-1-Dependent Manner - a Novel Link Between Aging, Caloric Restriction, and the Size of the Stem Cell Pool
Authors: Dong-Myung Shin, Wu Wan, Rui Liu, Janina Ratajczak, Andrzej Bartke, Magdalena Kucia, Mariusz Z Ratajczak
Journal: Blood (2010)
Preliminary Report from an Exploratory Phase II Trial with Plitidepsin (Aplidin®) in Patients with Refractory/Relapsed Multiple Myeloma.
Authors: M. V. Mateos, J. Blade, F. Prosper, J. J. Lahuerta, R. Garcia-Sanz, M. Cibeira, L. Rusiñol, F. Escalante, M. Ruiz, P. G. Richardson, J. F. San Miguel
Journal: Blood (2005)
Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure
Authors: Galina Gusarova, Anastasia Bykova, Alexandra Vorontsova, Sergey Kuznetsov, Oleg Shukhov, Ekaterina Chelysheva, Olga Lazareva, Svetlana Goryacheva, Tatyana Ivanova, Anna G. Turkina
Journal: Blood (2015)
Comparison of Rethrombosis-Free Survival in Children Versus Adults Suffering from Antithrombin-, Protein C- and Protein S-Deficiency: An Observational Multicenter Cohort Study
Authors: Verena Limperger, Gili Kenet, Christine Heller, Ralf Knoefler, Karin Kurnik, Ulrich C Klostermeier, Rolf Mesters, Neil A Goldenberg, Guy Young, Ulrike Nowak-Gottl
Journal: Blood (2015)
Impact of the Inhibitory KIR-HLA Receptor-Ligand Model on Unrelated Hematopoietic Stem Cell Transplantation in Patients with Leukemia.
Authors: Jun He, Zi-xing Chen, Xiao-jing Bao, De-pei Wu, Xiao-ni Yuan, Ai-ning Sun, Li Yao, Jian-nong Cen, Qiao-cheng Qiu
Journal: Blood (2007)
Harnessing Medical Training for Psychiatrists to Expand Access to Care
Authors: Melissa R. Arbuckle
Journal: American Journal of Psychiatry (2016)

Like the first author of the article, Dr. Vanderlip, I am also a double-boarded psychiatrist-family physician (actively working in both disciplines), and I engage in the treatment of psychiatric and general medical conditions during the same visit.Furthermore, in coordination with a social worker trained in supportive therapy, I teach family medicine residents to evaluate and treat these "combined" patients in a primary care setting.The best person to treat both psychiatric and comorbid medical conditions is someone practicing both.Absent that, rigorous psychiatric training for family physicians and general internists built into residency training allows for some crosstreatment.The management of general medical conditions in non-primary-care subspecialty settings should be viewed with caution to avoid undue risk to the patients in question.
Choosing and using lung function prediction equations
Authors: Martin R. Miller
Journal: European Respiratory Journal (2016)

In a survey of lung function laboratories some years ago, a surprisingly large number of laboratories were found not to know exactly which equations were being used to help them make judgements about their patients' results [1]. Many manufacturers' equipment includes a choice of reference values and the default selection may end up being used without further or due consideration. When choosing which equations to use, laboratory directors and clinicians may worry that their patients might be assessed against an inappropriate standard, thus introducing potential errors in their decision making. The European Respiratory Society has sponsored the Global Lung Function Initiative (GLI) in obtaining coherent reference equations for spirometry appropriate for all ages [2] and advocates these being the standard applied for spirometry within Europe. In this issue of the European Respiratory Journal ( ERJ ), two groups of European researchers have looked at their local populations to see if the GLI-2012 equations were a satisfactory fit and so can be safely used for clinical decision making [3, 4]. The GLI-2012 reference equations give the best fit for patients undergoing spirometry lung function testing <http://ow.ly/NikG304sh0n>
Biological markets explain human ultrasociality
Authors: Mark Sheskin, Stéphane Lambert, Nicolas Baumard
Journal: Behavioral and Brain Sciences (2016)

Abstract The evidence Gowdy &amp; Krall (G&amp;K) provide is more consistent with a biological markets explanation of human ultrasociality than a group selection explanation. Specifically, large-scale societies provide a better biological market for cooperation than do small-scale societies, allowing individuals to increase their fitness. Importantly, many of the quality-of-life costs G&amp;K discuss (e.g., patriarchy) are not fitness costs.
Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Revised International Prognostic Scoring System (IPSS-R)
Authors: Matteo Giovanni Della Porta, Emilio Paolo Alessandrino, Christopher H Jackson, Cristiana Pascutto, Andrea Bacigalupo, Luca Malcovati, Maria Teresa Van Lint, Bernardino Allione, Massimo Bernardi, Francesco Onida, Stefano Guidi, Anna Paola Iori, Raffaella Cerretti, Paola Marenco, Pietro Pioltelli, Emanuele Angelucci, Alberto Bosi, Mario Cazzola, Alessandro Rambaldi
Journal: Blood (2014)